Point mutations of the N‐ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia

  title={Point mutations of the N‐ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia},
  author={Valeri Vasioukhin and Philippe Anker and Pierre Maurice and Jacqueline Lyautey and Christine Lederrey and Maurice Stroun},
  journal={British Journal of Haematology},
Summary. Oncogene mutations are frequently found in several tumour types and, among these, point mutations of the ras gene are particularly significant. A predominance of N‐ras mutations has been found in the bone marrow DNA of patients with myelodysplatic syndrome (MDS) or acute myelogenous leukaemia (AML). On the other hand, increased levels of plasma DNA have previously been observed in patients suffering from various malignant diseases. In the present work we have investigated, by… 
Ras gene mutations in patients with acute myeloid leukaemia and exposure to chemical agents.
It is suggested that ras oncogene mutations might identify a group of leukaemia in people with previous X-ray/chemotherapy or with exposure to chemical agents in the work environment.
Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia.
It is concluded that PB plasma is enriched by tumor-specific DNA and can replace BM cells for studying genomic abnormalities and clonality was detectable in 19 (73%) of 26 BM samples, whereas all PB plasma samples showedClonality.
Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features.
  • T. Yamada, S. Nakamori, M. Monden
  • Medicine, Biology
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1998
It is suggested that K-ras gene mutation can be detected in plasma DNA of patients with pancreatic adenocarcinoma and may be clinically useful for evaluating tumor burden and efficacy of treatment.
Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients: follow-up study and prognostic significance.
  • R. Gonzalez, J. Silva, F. Bonilla
  • Medicine, Biology
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2000
Free plasma DNA with molecular alterations is present to a high degree in plasma DNA of SCLC patients and may have a role as a prognostic factor.
Detection of Circulating Tumour DNA in the Blood (Plasma/Serum) of Cancer Patients
The results obtained in many different cancers have opened a new research area indicating that plasma DNA might eventually be a suitable target for the development of non-invasive diagnostic, prognostic and follow-up tests for cancer.
Mutations in two neuroblastoma rat sarcoma oncogenes are associated with progression of haematologic malignancies in Nigeria
Mutations in codons 12 and 13 of NRAS gene in blood donors and haematologic malignant individuals using multiplex (AS-PCR) and Sanger sequencing are determined, highlighting the mutations as helpful diagnostic and prognostic tool.
Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA.
Plasma DNA assays for the detection of mutations in K-ras codon 12 may provide a feasible method to screen populations for somatic mutations frequently found in neoplasms and the clinical utility of using this test in screening populations requires further study.
TP53 Gene in Blood Plasma DNA of Tumor Patients
Tumor‐specific TP53 mutations are detectable in the blood plasma of tumor patients and the results of several mutation analyses were correlated with analysis of p53 autoantibodies in the same plasma.
p53 and APC Mutations Are Detectable in the Plasma and Serum of Patients with Colorectal Cancer (CRC) or Adenomas
It is suggested that all malignant and premalignant DNA alterations from the colon are identifiable in the blood and may have important implications for cancer screening and diagnosis in the large intestine.
A Prospective Study of Kras Mutations in the Plasma of Pancreatic Cancer Patients 1
The results indicate that K-ras mutations are often found in DNA isolated from the plasma of pancreatic cancer patients and that a noninvasive plasma-based assay may provide qualitative diagnostic information to clinicians in the future.


A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome
DNAs of bone-marrow cells from three out of eight patients with MDS contained an activated N-ras oncogene, as detected by an in vivo selection assay in nude mice with transfected NIH 3T3 cells, and molecular analysis revealed the same single nucleotide substitution at codon 13 in all three transformingN-ras genes.
The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing.
Results indicate that RAS mutations, especially those involving exon 1 of the N-RAS gene, are frequent only in a subset of hematologic malignancies.
Mutation analysis of the N‐ras proto‐oncogene in active and remission phase of human acute leukemias
It is shown that oligonucleotide hybridization is a sensitive assay for the detection of N‐ras point mutations, which in ANLL could be used to follow the fate of the leukemic clone during (and after) therapy.
RAS mutations in myelodysplasia detected by amplification, oligonucleotide hybridization, and transformation.
The results show that RAS mutations can occur at early, as well as late, stages of leukemic progression and the incidence of Ras mutations appears to be significantly higher in CMML than in the other subgroups.
Mutational activation of the N-ras oncogene assessed in primary clonogenic culture of acute myeloid leukemia (AML): implications for the role of N-ras mutation in AML pathogenesis.
The results suggest that N-ras mutation is a postinitiation event in AML that contributes to the outgrowth of more malignant subclones that may show different degrees of differentiation.
ras oncogenes in human cancer: a review.
  • J. L. Bos
  • Biology, Medicine
    Cancer research
  • 1989
It appeared that ras gene mutations can be found in a variety of tumor types, although the incidence varies greatly and some evidence that environmental agents may be involved in the induction of the mutations.
Relationship between an activated N-ras oncogene and chromosomal abnormality during leukemic progression from myelodysplastic syndrome.
Analysis with specific oligonucleotide probes revealed that bone marrow cells containing an activated N-ras oncogene proliferated in a dominant manner during the process of leukemic conversion in two patients with myelodysplastic syndrome.
Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease
The results indicate that serum DNA concentration is markedly elevated in malignancy, and moderately elevated in benign disease, as compared with normal controls, and may have diagnostic and prognostic value.
Isolation and characterization of DNA from the plasma of cancer patients.
Free DNA in the serum of cancer patients and the effect of therapy.
The relatively high percentage of cancer patients with apparently normal DNA levels would suggest that this radioimmunoassay may have low diagnostic value, but DNA in the serum may be an important tool for the evaluation of therapy or the comparison of different regimens.